ES3036330T3 - Imidazopyridazines as modulators of il-17 - Google Patents

Imidazopyridazines as modulators of il-17

Info

Publication number
ES3036330T3
ES3036330T3 ES21729078T ES21729078T ES3036330T3 ES 3036330 T3 ES3036330 T3 ES 3036330T3 ES 21729078 T ES21729078 T ES 21729078T ES 21729078 T ES21729078 T ES 21729078T ES 3036330 T3 ES3036330 T3 ES 3036330T3
Authority
ES
Spain
Prior art keywords
substituted
alkyl
methyl
groups
intermediate product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21729078T
Other languages
English (en)
Spanish (es)
Inventor
Douglas Behenna
Charlotte Deckhut
Alexander Rovira
Steven Goldberg
David Kummer
John Keith
Craig Woods
Timothy Rhorer
Virginia Tanis
connor Martin
Steven Meduna
Stefan Mccarver
Alexander Valdes
Steven Loskot
Xiaohua Xue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES3036330T3 publication Critical patent/ES3036330T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Fats And Perfumes (AREA)
  • Cosmetics (AREA)
  • Lubricants (AREA)
ES21729078T 2020-04-30 2021-04-28 Imidazopyridazines as modulators of il-17 Active ES3036330T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063017682P 2020-04-30 2020-04-30
PCT/US2021/029641 WO2021222404A1 (en) 2020-04-30 2021-04-28 Imidazopyridazines as modulators of il-17

Publications (1)

Publication Number Publication Date
ES3036330T3 true ES3036330T3 (en) 2025-09-17

Family

ID=76197556

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21729078T Active ES3036330T3 (en) 2020-04-30 2021-04-28 Imidazopyridazines as modulators of il-17

Country Status (20)

Country Link
US (3) US11691979B2 (cg-RX-API-DMAC10.html)
EP (1) EP4143195B1 (cg-RX-API-DMAC10.html)
JP (1) JP7664947B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230019507A (cg-RX-API-DMAC10.html)
CN (1) CN115884810B (cg-RX-API-DMAC10.html)
AR (1) AR121959A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021264528A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022021962A2 (cg-RX-API-DMAC10.html)
CA (1) CA3181676A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022017072A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP22091485A (cg-RX-API-DMAC10.html)
ES (1) ES3036330T3 (cg-RX-API-DMAC10.html)
IL (1) IL297705A (cg-RX-API-DMAC10.html)
JO (1) JOP20220284A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022013647A (cg-RX-API-DMAC10.html)
PE (1) PE20230469A1 (cg-RX-API-DMAC10.html)
TW (1) TWI874645B (cg-RX-API-DMAC10.html)
UY (1) UY39188A (cg-RX-API-DMAC10.html)
WO (1) WO2021222404A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202212967B (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201909190D0 (en) * 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
US12559496B2 (en) 2020-04-30 2026-02-24 Janssen Pharmaceutica Nv Imidazopyrimidines as modulators of IL-17
JP7664947B2 (ja) * 2020-04-30 2025-04-18 ヤンセン ファーマシューティカ エヌ.ベー. Il-17の調節因子としてのイミダゾリダジン
US20240140951A1 (en) * 2020-12-14 2024-05-02 UCB Biopharma SRL Imidazopyridazine derivatives as il-17 modulators
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
AU2022348938A1 (en) 2021-09-27 2024-05-16 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
AU2022349687A1 (en) 2021-09-27 2024-05-16 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
WO2023111181A1 (en) 2021-12-16 2023-06-22 Leo Pharma A/S Small molecule modulators of il-17
CN118580191A (zh) * 2022-01-28 2024-09-03 和记黄埔医药(上海)有限公司 用于制备咪唑并[1,2-b]哒嗪类化合物的中间体
EP4486737A1 (en) 2022-03-04 2025-01-08 LEO Pharma A/S Small molecule modulators of il-17
KR20250023378A (ko) * 2022-05-19 2025-02-18 다이스 알파, 인크. 락탐 치환된 이미다조피리다진 il-17a 조정제 및 그의 용도
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
CN115806503B (zh) * 2022-12-02 2025-03-07 中国海洋大学 一种选择性组蛋白去乙酰化酶抑制剂及其制备方法和应用
EP4688156A1 (en) * 2023-03-28 2026-02-11 Janssen Pharmaceutica NV Lactam-containing imidazopyridazine il-17 inhibitor compounds
WO2024215597A1 (en) * 2023-04-11 2024-10-17 Dice Alpha, Inc. Substituted 6-imidazopyridazine il-17a modulators and uses thereof
WO2025202931A1 (en) 2024-03-27 2025-10-02 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
WO2025247285A1 (zh) * 2024-05-28 2025-12-04 西藏海思科制药有限公司 一种可抑制il-17a的杂环化合物制备及其用途
WO2026080825A1 (en) * 2024-10-10 2026-04-16 Revolution Medicines, Inc. Synthesis of ras inhibitors
WO2026130488A1 (en) * 2024-12-18 2026-06-25 Anew Therapeutics Pte. Ltd. Heterocyclic compounds as il-17 inhibitors

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
EP2892899B1 (en) * 2012-09-06 2018-03-21 Bristol-Myers Squibb Company Imidazopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
WO2014066726A2 (en) 2012-10-26 2014-05-01 Ensemble Therapeutics Corporation Compounds for modulating il-17
WO2014181287A1 (en) 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
US10035777B2 (en) 2014-08-05 2018-07-31 Bristol-Myers Squibb Company Heterocyclic kinase inhibitors
KR102782807B1 (ko) * 2015-11-18 2025-03-14 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
GB201709456D0 (en) 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
CN111601799B (zh) * 2018-01-15 2023-06-09 Ucb生物制药有限责任公司 作为Il-17调节剂的稠合咪唑衍生物
WO2019223718A1 (zh) 2018-05-22 2019-11-28 成都先导药物开发股份有限公司 一种免疫调节剂
EP3599245A1 (en) 2018-07-27 2020-01-29 Dompé farmaceutici S.p.A. Il-17a binding polypeptides and medical uses thereof
GB201820166D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
GB201820165D0 (en) 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents
GB201820316D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for IL-17
MX2021006421A (es) 2018-12-19 2021-08-16 Leo Pharma As Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
TWI752400B (zh) * 2019-01-07 2022-01-11 美商美國禮來大藥廠 Il-17a抑制劑
CN113874080B (zh) 2019-02-06 2024-09-27 戴斯阿尔法公司 Il-17a调节剂及其用途
EP3935051A1 (en) 2019-03-08 2022-01-12 Leo Pharma A/S Small molecule modulators of il-17
GB201909191D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909194D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
WO2021027721A1 (zh) 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341442B (zh) 2019-08-09 2021-10-22 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341439B (zh) 2019-08-09 2022-02-15 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341451B (zh) 2019-08-09 2022-06-17 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021027722A1 (zh) 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341435B (zh) 2019-08-09 2021-10-22 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021027729A1 (zh) 2019-08-09 2021-02-18 成都先导药物开发股份有限公司 一种免疫调节剂
CN112341429B (zh) 2019-08-09 2021-11-23 成都先导药物开发股份有限公司 一种免疫调节剂的中间体化合物
CN112341450B (zh) 2019-08-09 2022-05-17 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021170631A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
WO2021170627A1 (en) 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
CN115702024A (zh) 2020-04-07 2023-02-14 Ucb生物制药有限责任公司 用作il-17调节剂的二氟环己基衍生物
WO2021204800A1 (en) 2020-04-07 2021-10-14 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
JP7664947B2 (ja) * 2020-04-30 2025-04-18 ヤンセン ファーマシューティカ エヌ.ベー. Il-17の調節因子としてのイミダゾリダジン
KR20230017211A (ko) * 2020-04-30 2023-02-03 얀센 파마슈티카 엔.브이. Il-17 경로의 조절인자를 식별하는 방법

Also Published As

Publication number Publication date
TWI874645B (zh) 2025-03-01
EP4143195A1 (en) 2023-03-08
MX2022013647A (es) 2023-02-01
CN115884810B (zh) 2025-01-17
US20220402922A1 (en) 2022-12-22
JP2023524018A (ja) 2023-06-08
US20230081548A1 (en) 2023-03-16
JOP20220284A1 (ar) 2022-10-30
ECSP22091485A (es) 2022-12-30
IL297705A (en) 2022-12-01
UY39188A (es) 2021-10-29
TW202208367A (zh) 2022-03-01
US12024524B2 (en) 2024-07-02
US20230357254A1 (en) 2023-11-09
EP4143195C0 (en) 2025-05-21
CN115884810A (zh) 2023-03-31
ZA202212967B (en) 2024-06-26
PE20230469A1 (es) 2023-03-14
WO2021222404A1 (en) 2021-11-04
JP7664947B2 (ja) 2025-04-18
CA3181676A1 (en) 2021-11-04
AU2021264528A1 (en) 2023-01-19
US11702422B2 (en) 2023-07-18
KR20230019507A (ko) 2023-02-08
AR121959A1 (es) 2022-07-27
CO2022017072A2 (es) 2022-12-09
EP4143195B1 (en) 2025-05-21
US11691979B2 (en) 2023-07-04
BR112022021962A2 (pt) 2023-03-28

Similar Documents

Publication Publication Date Title
JP7664947B2 (ja) Il-17の調節因子としてのイミダゾリダジン
CN102791693B (zh) 丙型肝炎病毒抑制剂
JP7558334B2 (ja) PI3K-γ阻害剤としてのアミノピラジンジオール化合物
JP5925394B2 (ja) 抗レトロウイルス剤としての(ヘテロ)アリールアセトアミド誘導体
US10287286B2 (en) Compounds
TWI922529B (zh) 化合物、組合物及方法
TW201038555A (en) Hepatitis C virus inhibitors
TW201100401A (en) Hepatitis C virus inhibitors
TW200934486A (en) Hepatitis C virus inhibitors
WO2017100668A1 (en) Inhibitors of bruton's tyrosine kinase and methods of their use
ES2906258T3 (es) 6-aminopiridin-3-ilo tiazoles como moduladores de ROR gamma t
JP6334066B2 (ja) ヤヌスキナーゼ阻害剤としての置換されたN−(ピロリジン−3−イル)−7H−ピロロ[2,3−d]ピリミジン−4−アミン
JP2024536862A (ja) Il-17の調節因子としてのベンズイミダゾール
KR20250136325A (ko) 염증성 질환 또는 바람직하지 않은 면역 반응과 연관된 질환을 치료 또는 예방하는 데 사용하기 위한 치환된 피리딘
BR112021001608A2 (pt) derivado de amida heteroaromático inovador e medicamento contendo o mesmo
WO2024233900A1 (en) Gsk3a inhibitors and methods of use thereof
WO2020187292A1 (zh) 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
ES2559295T3 (es) Un compuesto para el tratamiento de la hepatitis C
EA049631B1 (ru) Имидазопиридазины в качестве модуляторов il-17
HK40067217A (en) Ep2 antagonist
HK40044910A (en) Modulators of the integrated stress pathway